Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin: 2016-2024

Historic EBT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -43.33%.

  • Akebia Therapeutics' EBT Margin rose 5551.00% to 1.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.79%, marking a year-over-year decrease of 31873.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • Akebia Therapeutics' EBT Margin amounted to -43.33% in FY2024, which was up 91.65% from -519.25% recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' EBT Margin peaked at -32.22% during FY2022, and registered a low of -519.25% during FY2023.
  • Its 3-year average for EBT Margin is -198.27%, with a median of -43.33% in 2024.
  • Per our database at Business Quant, Akebia Therapeutics' EBT Margin skyrocketed by 273,229bps in 2020 and then slumped by 48,703bps in 2023.
  • Yearly analysis of 5 years shows Akebia Therapeutics' EBT Margin stood at -130.61% in 2020, then plummeted by 264bps to -133.25% in 2021, then spiked by 10,103bps to -32.22% in 2022, then slumped by 48,703bps to -519.25% in 2023, then soared by 47,592bps to -43.33% in 2024.